查詢結果分析
來源資料
相關文獻
- 睪丸支持細胞在巴金森氏症神經移植治療的應用
- 體外培養之胚胎中腦細胞在巴金森氏症神經移植治療的應用
- 神經移植治療巴金森氏症鼠
- The Effects of Dopamine D-1 and D-2 Receptor Subtype Agonists on Nigrostriatal Opioid Dynorphin and Enkephalin Immunostaining in 6-Hydroxydopamine Lesioned Rats
- The Effects of Dopamine D-1 and D-2 Receptor Subtype Agonists on Nigrostriatal Opioid Dynorphin and Enkephalin Immunostaining in 6-Hydroxydopamine Lesioned Rats
- 神經移植治療巴金森氏症之研究
- 帕金森氏症候群中醫證治
- Isokinetic Strength and Electromyographic Analysis of Knee Muscles in Parkinsonian Patients and Normal Subjects
- 大腦蒼白球切開術的發展簡史
- 巴金森氏症之新知--病因、治療與護理
頁籤選單縮合
題名 | 睪丸支持細胞在巴金森氏症神經移植治療的應用=Neurotransplantation of Testis-Derived Sertoli Cells in the Treatment of Parkinson's Disease |
---|---|
作者姓名(中文) | 劉鴻文; 匡亞珍; 徐漢業; 李憶玲; 馬國興; 王順德; 劉江川; | 書刊名 | 醫學研究 |
卷期 | 19:2 1998.09[民87.09] |
頁次 | 頁71-83 |
分類號 | 415.83 |
關鍵詞 | 巴金森氏症; 神經移植; 睪丸支持細胞; 紋狀體; 黑質; Parkinson's disease; Neurotransplantation; Sertoli cells; Striatum; Substantia nigra; |
語文 | 中文(Chinese) |
中文摘要 | 隨著人類壽命的延長,巴金森氏症(Parkinson's disease)、老年失智症等老化有關的疾病也逐年增加;依西方國家的盛行率推算,臺灣約有三萬人罹患此病症。因此巴金森氏症的預防及治療是全民醫療保健一個極為重要的課題。英國醫師James Parkinson於1817年,即對巴金森氏症的臨床表徵有相當完整和詳盡的描述。多年來的研究結果顯示巴金森氏症是一種慢性、進行腦黑質紋狀體徑(nigrostriatal tract)中,缺乏多巴胺(dopamine)所引起的中樞神經系統疾病;而臨床上,將巴金森氏症定義為:「具有震顫(tremor)、僵直(rigidity)及行動遲緩(bradykinesia)等特殊症狀之漸進性神經病變」。其致病原因,目前並不完全清楚;但以多巴胺代謝過程中所引發之過度氧化壓力(oxidative stress),導致多巴胺神經細胞選擇性退化的學說較為學者所重視。由於多巴胺不能穿過血腦障壁;而其前趨物,L-dopa可以通過,並可在紋狀體由多巴去羧�t轉變成多巴胺,所以臨床上多以口服此藥來治療。但服用數年後,其藥效會逐漸衰減,患者的症狀也因控制不良而惡化。此外,L-dopa常伴有姿勢性低血壓、心律不整及不隨意運動等副作用。因此學者正積極發展神經移植的治療方式,嘗試將胎兒黑質組織移植到患者腦中,以補充退化的多巴胺神經細胞。神經移植治療雖然具有潛力;但免疫排斥、神經組織的取得和存活等問題有待妥善解決。由於睪丸支持細胞可以分泌免疫抑制及細胞滋養因子,因此Sanberg等學者嘗試將睪丸支持細胞應用於巴金森氏症的神經移植治療。本實驗室最近以睪丸支持細胞移植到6-OHDA誘發之巴金森症大白鼠的紋狀體中,探討睪丸支持細胞在神經移植治療中可能的應用。移植後雖未使用cyclosporine A等免疫抑制藥物,然而安非他命誘發之旋轉行為有明顯的改善;紋狀體和黑質多巴胺神經中酪胺酸羥化�t的含量皆有明顯的恢復;這些結果顯示睪丸支持細胞具有免疫抑制與神經滋養的作用,在巴金森氏症的治療上深具潛力。 |
英文摘要 | It is estimated that 30,000 new case of Parkinson's disease will be diagnosed each year in Taiwan. Therefore, strategy for prevention and treatment toward Parkinson's disease is worthy of pursuing. It is generally accepted that Parkinson's disease is a chronic, progressive central nervous disorder resulted from dopamine-deficiency in nigrostriatal tract. L-dopa, a precursor of dopamine that may be transported through blood-brain barrier, and decarboxylated to dopamine in striatum, is the most common remedy used for the disease. Since on-off and other side effect of L-dopa, neurotransplantation of dopaminergic neuron to replace degenerated neuron is being investigated with some promising results. However, immunorejection, source and survival of the nigral tissue need to be improved. Sanberg and his colleague demonstrated that xenograft of testisderived Sertoli cells may survive in normal striatum for more than 2 months without immunosuppresive drugs. In addition, our recent studies revealed Sertoli cells transplanted into striatum of 6-OHDA lesioned Parkinsonian rats migth survive for 12 weeks, and improved amphetamine-induced rotation, and restored tyrosine hydroxylase in striatum and substantia nigra. There results indicated that Sertoli cells exhibited immunosuppresive and neurotrophic effects, and neurotransplantation of Sertoli cells might be a potential treatment for Parkinson's disease. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。